tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Abnormalities, Multiple D000015 13 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Acne Vulgaris D000152 35 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Akinetic Mutism D000405 1 associated lipids
Albuminuria D000419 18 associated lipids
Alopecia D000505 14 associated lipids
Alopecia Areata D000506 6 associated lipids
Alzheimer Disease D000544 76 associated lipids
Amenorrhea D000568 4 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Anemia D000740 21 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Anemia, Refractory D000753 3 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Aneurysm, Dissecting D000784 2 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Angioedema D000799 6 associated lipids
Anus Diseases D001004 3 associated lipids
Apraxias D001072 1 associated lipids
Arm Injuries D001134 1 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Arthritis, Juvenile D001171 8 associated lipids
Ascites D001201 25 associated lipids
Ataxia D001259 20 associated lipids
Ataxia Telangiectasia D001260 6 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Bacterial Infections D001424 21 associated lipids
Balanitis D001446 4 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Behcet Syndrome D001528 7 associated lipids
Biliary Fistula D001658 13 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Blepharitis D001762 4 associated lipids
Blindness D001766 6 associated lipids
Body Weight D001835 333 associated lipids
Bone Diseases D001847 4 associated lipids
Bradycardia D001919 13 associated lipids
Brain Diseases D001927 27 associated lipids
Brain Edema D001929 20 associated lipids
Bronchiolitis D001988 6 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Burkitt Lymphoma D002051 15 associated lipids
Burns D002056 34 associated lipids
Candidiasis, Oral D002180 11 associated lipids
Candidiasis, Vulvovaginal D002181 8 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Cardiomyopathy, Hypertrophic D002312 6 associated lipids
Cardiomyopathy, Restrictive D002313 1 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Catalepsy D002375 30 associated lipids
Cataract D002386 34 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Cheilitis D002613 2 associated lipids
Cholelithiasis D002769 16 associated lipids
Cholestasis D002779 23 associated lipids
Choline Deficiency D002796 16 associated lipids
Hemophilia B D002836 3 associated lipids
Chronic Disease D002908 7 associated lipids
Cicatrix D002921 9 associated lipids
Coccidioidomycosis D003047 2 associated lipids
Colitis D003092 69 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Collagen Diseases D003095 2 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Confusion D003221 4 associated lipids
Connective Tissue Diseases D003240 2 associated lipids
Corneal Diseases D003316 13 associated lipids
Cough D003371 19 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Crohn Disease D003424 12 associated lipids
Cryptococcosis D003453 3 associated lipids
Cutis Laxa D003483 1 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Cystitis D003556 23 associated lipids
Phyllodes Tumor D003557 1 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Deglutition Disorders D003680 2 associated lipids
Dehydration D003681 11 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Dental Enamel Hypoplasia D003744 2 associated lipids
Dental Pulp Calcification D003784 2 associated lipids
Dermatitis D003872 30 associated lipids
Drug Eruptions D003875 30 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Perlman RL and Rao PS Quality of life of older patients undergoing renal transplantation: finding the right immunosuppressive treatment. 2014 Drugs Aging pmid:24399579
Tanaka K et al. Significant association between CYP3A5 polymorphism and blood concentration of tacrolimus in patients with connective tissue diseases. 2014 J. Hum. Genet. pmid:24352002
Kim EJ et al. Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. 2014 Am. J. Transplant. pmid:24354871
Huang K et al. Novel role for NFAT3 in ERK-mediated regulation of CXCR4. 2014 PLoS ONE pmid:25514788
Cho JH et al. Development of novel fast-dissolving tacrolimus solid dispersion-loaded prolonged release tablet. 2014 Eur J Pharm Sci pmid:24388864
Saito K et al. Severe diffuse duodenitis successfully treated with intravenous tacrolimus after colectomy for ulcerative colitis. 2014 Intern. Med. pmid:25366006
Labrador J et al. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus. 2014 Bone Marrow Transplant. pmid:24566710
Singh K et al. Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. 2014 Am. J. Transplant. pmid:25359003
Siebelt M et al. FK506 protects against articular cartilage collagenous extra-cellular matrix degradation. 2014 Osteoarthr. Cartil. pmid:24561282
Tang Q Pharmacokinetics of therapeutic Tregs. 2014 Am. J. Transplant. pmid:25358900
Pereira MJ et al. Cyclosporine A and tacrolimus reduce the amount of GLUT4 at the cell surface in human adipocytes: increased endocytosis as a potential mechanism for the diabetogenic effects of immunosuppressive agents. 2014 J. Clin. Endocrinol. Metab. pmid:25004245
Diémé B et al. Assessing the metabolic effects of calcineurin inhibitors in renal transplant recipients by urine metabolic profiling. 2014 Transplantation pmid:24598938
Grillo E et al. Necrobiosis lipoidica. 2014 Aust Fam Physician pmid:24600675
Kimura Y et al. Evaluation of the Multi-ImmunoTox Assay composed of 3 human cytokine reporter cells by examining immunological effects of drugs. 2014 Toxicol In Vitro pmid:24603311
Shilbayeh S The impact of genetic polymorphisms on time required to attain the target tacrolimus levels and subsequent pharmacodynamic outcomes in pediatric kidney transplant patients. 2014 Saudi J Kidney Dis Transpl pmid:24625991
Sagiroglu T et al. Protective effect of everolimus on renal ischemia reperfusion injury in rats. 2014 Saudi J Kidney Dis Transpl pmid:24625994
Xue F et al. CYP3A5 genotypes affect tacrolimus pharmacokinetics and infectious complications in Chinese pediatric liver transplant patients. 2014 Pediatr Transplant pmid:24438215
Wang XZ et al. Increased intracellular adenosine triphosphate level as an index to predict acute rejection in kidney transplant recipients. 2014 Transpl. Immunol. pmid:24211610
Lapeyraque AL et al. Conversion from twice- to once-daily tacrolimus in pediatric kidney recipients: a pharmacokinetic and bioequivalence study. 2014 Pediatr. Nephrol. pmid:24435759
Højfeldt JW et al. Bifunctional ligands allow deliberate extrinsic reprogramming of the glucocorticoid receptor. 2014 Mol. Endocrinol. pmid:24422633
Golubović B et al. Total plasma protein effect on tacrolimus elimination in kidney transplant patients--population pharmacokinetic approach. 2014 Eur J Pharm Sci pmid:24184751
Saso S et al. Uterine allotransplantation in a rabbit model using aorto-caval anastomosis: a long-term viability study. 2014 Eur. J. Obstet. Gynecol. Reprod. Biol. pmid:25306223
Mekaj AY et al. Application of topical pharmacological agents at the site of peripheral nerve injury and methods used for evaluating the success of the regenerative process. 2014 J Orthop Surg Res pmid:25303779
Satoh S et al. Pharmacokinetic and CYP3A5 pharmacogenetic differences between once- and twice-daily tacrolimus from the first dosing day to 1 year after renal transplantation. 2014 Pharmacogenomics pmid:25303300
Meyer KC et al. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. 2014 Eur. Respir. J. pmid:25359357
Souto-Rodríguez R et al. Differences in the incidence and clinical evolution of early neurotoxicity after liver transplantation based on tacrolimus formulation used in the immunosuppressive induction protocol. 2014 Transplant. Proc. pmid:25420839
de la Fuente S et al. Long-term survivors after pediatric liver transplatation are at increased risk for development of cardiovascular disease events: analysis of 30 cases. 2014 Transplant. Proc. pmid:25420837
Masson P et al. Belatacept for kidney transplant recipients. 2014 Cochrane Database Syst Rev pmid:25416857
Salehi-Najafabadi Z et al. The gamma-butyrolactone receptors BulR1 and BulR2 of Streptomyces tsukubaensis: tacrolimus (FK506) and butyrolactone synthetases production control. 2014 Appl. Microbiol. Biotechnol. pmid:24562179
Xue W et al. Effects of tacrolimus and cyclosporine treatment on metabolic syndrome and cardiovascular risk factors after renal transplantation: a meta-analysis. 2014 Chin. Med. J. pmid:24931259
Lalić J et al. Immunosuppressive medication adherence in kidney transplant patients. 2014 Med Princ Pract pmid:24923773
Gijsen VM et al. P450 oxidoreductase *28 (POR*28) and tacrolimus disposition in pediatric kidney transplant recipients--a pilot study. 2014 Ther Drug Monit pmid:24089076
Funaro D et al. A double-blind, randomized prospective study evaluating topical clobetasol propionate 0.05% versus topical tacrolimus 0.1% in patients with vulvar lichen sclerosus. 2014 J. Am. Acad. Dermatol. pmid:24704090
Doligalski CT et al. Sublingual administration of tacrolimus: current trends and available evidence. 2014 Pharmacotherapy pmid:25251980
Demmers MW et al. Limited efficacy of immunosuppressive drugs on CD8+ T cell-mediated and natural killer cell-mediated lysis of human renal tubular epithelial cells. 2014 Transplantation pmid:24704664
Koren G and Rieder M Measuring oral bioavailability of tacrolimus. 2014 Pediatr Transplant pmid:25250966
Størset E et al. Importance of hematocrit for a tacrolimus target concentration strategy. 2014 Eur. J. Clin. Pharmacol. pmid:24071959
Rahman Z et al. Determination of tacrolimus crystalline fraction in the commercial immediate release amorphous solid dispersion products by a standardized X-ray powder diffraction method with chemometrics. 2014 Int J Pharm pmid:25173870
Jia JJ et al. ''Minimizing tacrolimus'' strategy and long-term survival after liver transplantation. 2014 World J. Gastroenterol. pmid:25170223
Hao JC et al. Effect of low-dose tacrolimus with mycophenolate mofetil on renal function following liver transplantation. 2014 World J. Gastroenterol. pmid:25170222
Elens L et al. Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients. 2014 Ther Drug Monit pmid:24061445
Huang H et al. Effect and mechanism of tacrolimus on melanogenesis on A375 human melanoma cells. 2014 Chin. Med. J. pmid:25131236
Vattemi G et al. Polymyositis in solid organ transplant recipients receiving tacrolimus. 2014 J. Neurol. Sci. pmid:25130930
Guy S et al. Successful treatment of acute severe graft-versus-host-disease in a pancreas-after-kidney transplant recipient: case report. 2014 Transplant. Proc. pmid:25179161
Bercaw-Pratt JL et al. Clinical recommendation: pediatric lichen sclerosus. 2014 J Pediatr Adolesc Gynecol pmid:24602304
Yuan C et al. A simple and robust LC-MS/MS method for measuring sirolimus and everolimus in whole blood. 2014 Bioanalysis pmid:25077621
Kaieda S et al. Successful treatment of rectal ulcers in a patient with systemic lupus erythematosus using corticosteroids and tacrolimus. 2014 Mod Rheumatol pmid:24593214
Aulagnon F et al. Diarrhea after kidney transplantation: a new look at a frequent symptom. 2014 Transplantation pmid:25073040
Bica L et al. Neuroprotective copper bis(thiosemicarbazonato) complexes promote neurite elongation. 2014 PLoS ONE pmid:24587210
Little JA et al. The safety and efficacy of noncorticosteroid triple immunosuppressive therapy in the treatment of refractory chronic noninfectious uveitis in childhood. 2014 J. Rheumatol. pmid:24085549
Bergmann TK et al. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose. 2014 Ther Drug Monit pmid:24089074
Beermann KJ et al. Tacrolimus dose requirements in African-American and Caucasian kidney transplant recipients on mycophenolate and prednisone. 2014 Clin Transplant pmid:24754564
Denfield SW Oxidative and other stresses following pediatric heart transplantation. 2014 Pediatr Transplant pmid:25250969
Izumi Y et al. Safety of tacrolimus treatment during pregnancy and lactation in systemic lupus erythematosus: a report of two patients. 2014 Tohoku J. Exp. Med. pmid:25175032
Personett HA et al. Impact of molecular adsorbent recirculating system therapy on tacrolimus elimination: a case report. 2014 Transplant. Proc. pmid:25017243
Anderson JS et al. Statistical allosteric coupling to the active site indole ring flip equilibria in the FK506-binding domain. 2014 Biophys. Chem. pmid:25016286
van Gelder T et al. Pharmacogenetics and immunosuppressive drugs in solid organ transplantation. 2014 Nat Rev Nephrol pmid:25247332
Tapirdamaz Ö et al. Genetic variance in ABCB1 and CYP3A5 does not contribute toward the development of chronic kidney disease after liver transplantation. 2014 Pharmacogenet. Genomics pmid:25014506
Helmschrott M et al. Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen. 2014 Drug Des Devel Ther pmid:25246772
Matta C et al. Ser/Thr-phosphoprotein phosphatases in chondrogenesis: neglected components of a two-player game. 2014 Cell. Signal. pmid:25007994
Matsuda Y et al. Once-daily oral administration of cyclosporine in a lung transplant patient with a history of renal toxicity of calcineurin inhibitors. 2014 Interact Cardiovasc Thorac Surg pmid:24659549
Hara H et al. Hematopoietic chimerism following allotransplantation of the spleen, splenocytes or kidney in pigs. 2014 Transpl. Immunol. pmid:25245436
Lunde I et al. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. 2014 Eur. J. Clin. Pharmacol. pmid:24658827
Picchianti-Diamanti A et al. P-glycoprotein and drug resistance in systemic autoimmune diseases. 2014 Int J Mol Sci pmid:24658440
Rostaing L et al. The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study. 2014 Ann. Transplant. pmid:25017487
Jannot M et al. Early conversion from twice-daily tacrolimus to once-daily extended formulation in renal transplant patients before hospital discharge. 2014 Ann. Transplant. pmid:24999809
Wannhoff A et al. Increased levels of rivaroxaban in patients after liver transplantation treated with cyclosporine A. 2014 Transplantation pmid:25022236
Sureshkumar KK and Chopra B In search of an optimal induction agent in kidney transplantation. 2014 Transplantation pmid:24978038
Welberry Smith MP and Baker RJ The author's reply. 2014 Transplantation pmid:24978039
Singla AK et al. Cerulomycin Caerulomycin [corrected] A: a potent novel immunosuppressive agent. 2014 Transplantation pmid:24949498
Andrade-Sierra J et al. Early steroid withdrawal in a renal transplant cohort treated with tacrolimus, mycophenolate mofetil and basiliximab. 2014 Nefrologia pmid:24658197
Enderby CY et al. Tacrolimus dosage requirements in lung transplant recipients receiving antifungal prophylaxis with voriconazole followed by itraconazole: a preliminary prospective study. 2014 Clin Transplant pmid:24931421
Webster P et al. Tacrolimus is an effective treatment for lupus nephritis in pregnancy. 2014 Lupus pmid:24928830
Wolfram D et al. Insights from computational modeling in inflammation and acute rejection in limb transplantation. 2014 PLoS ONE pmid:24926998
Zhao X et al. [A retrospective cohort study regarding the effect of sirolimus-based immunosuppression protocol on the long-term survival of hepatocellular carcinoma patients after liver transplantation]. 2014 Zhonghua Wai Ke Za Zhi pmid:24924566
Carbajo-Lozoya J et al. Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir. 2014 Virus Res. pmid:24566223
Rotter D et al. Calcineurin and its regulator, RCAN1, confer time-of-day changes in susceptibility of the heart to ischemia/reperfusion. 2014 J. Mol. Cell. Cardiol. pmid:24838101
Ren Y et al. Tolerogenic dendritic cells modified by tacrolimus suppress CD4(+) T-cell proliferation and inhibit collagen-induced arthritis in mice. 2014 Int. Immunopharmacol. pmid:24836681
Li H et al. A promising approach of overcoming the intrinsic resistance of Candida krusei to fluconazole (FLC)--combining tacrolimus with FLC. 2014 FEMS Yeast Res. pmid:24830342
Wang YB et al. In vitro and in vivo performance of dry powder inhalation formulations: comparison of particles prepared by thin film freezing and micronization. 2014 AAPS PharmSciTech pmid:24824172
Oda K et al. In vitro experimental system for evaluating inhibitory effect of investigational drugs on P-glycoprotein-mediated transcellular transport of tacrolimus (FK506). 2014 Biopharm Drug Dispos pmid:24822242
Wang Z et al. Influence of TLR4 rs1927907 locus polymorphisms on tacrolimus pharmacokinetics in the early stage after liver transplantation. 2014 Eur. J. Clin. Pharmacol. pmid:24820765
Welzl K et al. Effect of different immunosuppressive drugs on immune cells from young and old healthy persons. 2014 Gerontology pmid:24434865
Yang LM et al. Experimental research on end-to-side anastomosis of peripheral nerves and effect of FK506 on end-to-side anastomosis. 2014 Bratisl Lek Listy pmid:25573729
Colom H et al. Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients. 2014 Kidney Int. pmid:24402086
Muduma G et al. A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability. 2014 J Med Econ pmid:24754700
Shihab FS et al. Tacrolimus exposure in the real world: an analysis from the Mycophenolic acid Observational REnal transplant study. 2014 Clin Transplant pmid:24754603
Parashos SA et al. Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. 2014 JAMA Neurol pmid:24711047
Taube D et al. Generic tacrolimus in solid organ transplantation. 2014 Clin Transplant pmid:24750309
Bloch J et al. Donor ABCB1 genetic polymorphisms influence epithelial-to-mesenchyme transition in tacrolimus-treated kidney recipients. 2014 Pharmacogenomics pmid:25521359
Gillard P et al. Early alteration of kidney function in nonuremic type 1 diabetic islet transplant recipients under tacrolimus-mycophenolate therapy. 2014 Transplantation pmid:24770614
Nacif LS et al. An analysis of tacrolimus-related complications in the first 30 days after liver transplantation. 2014 Clinics (Sao Paulo) pmid:25518032
Varghese J et al. Tacrolimus-related adverse effects in liver transplant recipients: its association with trough concentrations. 2014 Indian J Gastroenterol pmid:24740447
Mitsides N et al. Dapsone-induced methemoglobinemia in renal transplant recipients: more prevalent than previously thought. 2014 Transpl Infect Dis pmid:24215452
Kawaguch K et al. Successful treatment with allogenic hematopoietic stem cell transplantation of a severe congenital neutropenia patient harboring a novel ELANE mutation. 2014 Rinsho Ketsueki pmid:25501410
Cvetkovic TP et al. Gender differences in oxidative and nitrosative stress parameters in kidney transplant patients on tacrolimus-based immunosuppression. 2014 Int Urol Nephrol pmid:24101297
Chen Y et al. Comparison of long-term impact of immunosuppressants at therapeutic doses on hepatic function and histological changes in unilateral nephrectomized rats. 2014 Exp. Toxicol. Pathol. pmid:25081300
Elens L et al. Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks. 2014 Br J Clin Pharmacol pmid:24118098
Langers P et al. Limited sampling model for advanced mycophenolic acid therapeutic drug monitoring after liver transplantation. 2014 Ther Drug Monit pmid:24081208
da Cunha Filho RR et al. "Angular" plasma cell cheilitis. 2014 Dermatol. Online J. pmid:24656273